China-based biopharma Antengene Corp., Ltd (HKG: 6996) announced that its Xpovio (selinexor), the world’s first FDA-approved oral XPO1 inhibitor, has been included in Taiwan’s National Health Insurance (NHI) drug list. The approved indication is for use in combination with bortezomib and dexamethasone in adults previously treated with one therapy for relapsed or refractory multiple myeloma (R / R MM).
Drug Background
Discovered by US-based Karyopharm Therapeutics Inc. (NASDAQ: KPTI), Xpovio was licensed to Antengene for rights in Greater China, South Korea, and ASEAN countries in May 2018. The drug received conditional approval in China in November 2021 for use in multiple myeloma (MM). It has since gained marketing approvals in Taiwan, Hong Kong, Macau, South Korea, Singapore, and Australia.-Fineline Info & Tech
